ATLANTA, April 26 /PRNewswire-FirstCall/ -- Inhibitex, Inc. announced today it will host a conference call on Friday, May 5, 2006 at 8:30 a.m. ET to review its first quarter 2006 financial results and provide an update on corporate developments. The Company will issue a press release on the same day, prior to the conference call.
To access the conference call, please dial 866-713-8565 (domestic) or 617- 597-5324 (international) and reference the access code 45026871. A replay of the call will be available from 10:30 a.m. ET on May 5, until June 5, 2006 at midnight. To access the replay, please dial 888-286-8010 (domestic) or 617- 801-6888 (international) and reference the access code 98914064. A live audio webcast of the call and the archived webcast will be available in the Investors section of the Inhibitex website http://www.inhibitex.com.
About Inhibitex
Inhibitex, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of antibody-based products for the prevention and treatment of serious, life-threatening infections. All of the company's drug development programs are based on its proprietary MSCRAMM(R) protein platform. MSCRAMM proteins are located on the surface of pathogenic organisms, and are responsible for the initiation and spread of infections. The company's most advanced product candidates are Veronate(R) and Aurexis(R), for which the company has retained all worldwide rights. The company's preclinical programs include a collaboration and joint development agreement with Dyax to develop fully human monoclonal antibodies against MSCRAMM proteins on enterococci and a partnership with Wyeth to develop staphylococcal vaccines.
Inhibitex(R), MSCRAMM(R), Veronate(R) and Aurexis(R) are registered trademarks of Inhibitex, Inc.
Inhibitex, Inc.CONTACT: Russell H. Plumb, Chief Financial Officer of Inhibitex, Inc.,+1-678-746-1136, or rplumb@inhibitex.com; or Investors, Lilian Stern ofStern Investor Relations, Inc., +1-212-362-1200, or lilian@sternir.com
Web site: http://www.inhibitex.com//
